Polycystic Ovary Syndrome and Risk of Type 2 Diabetes, Coronary Heart Disease, and Stroke
The DOI matches its Crossref record; 49 of the 53 references it cites were found in a registry or an index.
Abstract
Polycystic ovary syndrome (PCOS) has been associated with diabetes and cardiovascular disease; however, whether the relationship is causal is uncertain. We conducted a two-sample Mendelian randomization study to investigate the associations of PCOS with type 2 diabetes, coronary heart disease (CHD), and stroke. Association between PCOS and diabetes risk was examined in European and Asian cohorts, both sex specific and sex combined. Causal effects of PCOS on risks of CHD and stroke were evaluated in European cohorts. Stroke was analyzed as any stroke as well as four subtypes of stroke (ischemic, large artery, cardioembolic, small vessel). We found no association of genetically predicted PCOS with risk of diabetes, CHD, or stroke. This suggests that PCOS in and of itself does not increase the risk of these outcomes. Other features of PCOS (obesity, elevated testosterone, low sex hormone binding globulin) may explain the association between PCOS and cardiometabolic diseases. In light of these results, efforts to prevent cardiometabolic complications in PCOS should focus on women with high-risk features rather than all women with PCOS.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Obesity, insulin resistance, and dyslipidemia are common clinical features in women with PCOS and increase the risk for cardiometabolic diseases and reproductive cancers by ≥50% [3]”
From Availability and Use of Digital Technology Among Women With Polycystic Ovary Syndrome: Scoping Review (2025) · cites this paper as [3]
Citations
Cites
Bowden, J., Davey Smith, G., & Burgess, S. (2015) · International Journal of Epidemiology · doi:10.1093/ije/dyv080 · Cited by 9,816 · cited 6×
“In all cases, the MR-Egger intercepts were not different from zero, indicating absence of directional pleiotropy.”
BackgroundMethodInfluentialBowden, J., Davey Smith, G., Haycock, P. C., & Burgess, S. (2016) · Genetic Epidemiology · doi:10.1002/gepi.21965 · Cited by 8,922 · cited 2×
“The weighted median approach can provide a consistent causal effect estimate as long as at least 50% of the information contributing to the analysis comes from valid instrumental variables (20).”
BackgroundMethodThe MR-Base platform supports systematic causal inference across the human phenome
Hemani, G., Zheng, J., Elsworth, B., Wade, K. H., Haberland, V., Baird, D., Laurin, C., Burgess, S., Bowden, J., Langdon, R., et al. (2018) · eLife · doi:10.7554/elife.34408 · Cited by 7,959 · cited 2×
“We used R 3.6.3 software and the R package TwoSampleMR (22) for the analyses.”
MethodInfluentialBurgess, S., Bowden, J., Fall, T., Ingelsson, E., & Thompson, S. G. (2017) · Epidemiology · doi:10.1097/ede.0000000000000559 · Cited by 2,017
A framework for the investigation of pleiotropy in two‐sample summary data Mendelian randomization
Bowden, J., Del Greco M, F., Minelli, C., Davey Smith, G., Sheehan, N., & Thompson, J. (2017) · Statistics in Medicine · doi:10.1002/sim.7221 · Cited by 1,887 · cited 1×
“Primary MR analyses were conducted with the inverse variance weighted (IVW) method with random effects (18).”
MethodMahajan, A., Taliun, D., Thurner, M., Robertson, N. R., Torres, J. M., Rayner, N. W., Payne, A. J., Steinthorsdottir, V., Scott, R. A., Grarup, N., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0241-6 · Cited by 1,744
Legro, R. S. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.1.165 · Cited by 1,743 · cited 1×
“However, some studies that did attempt to match for or statistically adjust for BMI reported positive association between PCOS and diabetes (25,31,32).”
ResultMalik, R., Chauhan, G., Traylor, M., Sargurupremraj, M., Okada, Y., Mishra, A., Rutten-Jacobs, L., Giese, A.-K., van der Laan, S. W., Gretarsdottir, S., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0058-3 · Cited by 1,599
Bowden, J., Del Greco M., F., Minelli, C., Davey Smith, G., Sheehan, N. A., & Thompson, J. R. (2016) · International Journal of Epidemiology · doi:10.1093/ije/dyw220 · Cited by 1,565
Pulit, S. L., Stoneman, C., Morris, A. P., Wood, A. R., Glastonbury, C. A., Tyrrell, J., Yengo, L., Ferreira, T., Marouli, E., Ji, Y., et al. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddy327 · Cited by 1,163
Cited by
Stener-Victorin, E., Teede, H., Norman, R. J., Legro, R., Goodarzi, M. O., Dokras, A., Laven, J., Hoeger, K., & Piltonen, T. T. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00511-3 · Cited by 495
“However, another Mendelian randomization analysis did not find a causal role for PCOS in T2DM, coronary heart disease or stroke, suggesting that PCOS and cardiometabolic disease share common underpinnings (for example, obesity) rather than a causal relationship 91 .”
Self-citationDeconstructing a Syndrome: Genomic Insights Into PCOS Causal Mechanisms and Classification
Dapas, M., & Dunaif, A. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac001 · Cited by 300
Polycystic ovary syndrome as a metabolic disease
Helvaci, N., & Yildiz, B. O. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-01057-w · Cited by 188
Polycystic ovary syndrome: a “risk-enhancing” factor for cardiovascular disease
Guan, C., Zahid, S., Minhas, A. S., Ouyang, P., Vaught, A., Baker, V. L., & Michos, E. D. (2022) · Fertility and Sterility · doi:10.1016/j.fertnstert.2022.03.009 · Cited by 188
Heidarzadehpilehrood, R., Pirhoushiaran, M., Abdollahzadeh, R., Osman, M. B., Sakinah, M., Nordin, N., & Hamid, H. A. (2022) · Genes · doi:10.3390/genes13020302 · Cited by 152
“The most important risk factors for this cancer include polycystic ovary syndrome, diabetes, and obesity [104].”
BackgroundCauses and Consequences of Polycystic Ovary Syndrome: Insights From Mendelian Randomization
Zhu, T., & Goodarzi, M. O. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab757 · Cited by 126
Self-citationCao, J., Huo, P., Cui, K., Wei, H., Cao, J., Wang, J., Liu, Q., Lei, X., & Zhang, S. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00876-6 · Cited by 134
Polycystic ovary syndrome and type 2 diabetes mellitus: A state-of-the-art review
Livadas, S., Anagnostis, P. G., Bosdou, J. Κ., Bantouna, D., & Paparodis, R. D. (2022) · World Journal of Diabetes · doi:10.4239/wjd.v13.i1.5 · Cited by 130
Guo, F., Gong, Z., Fernando, T., Zhang, L., Zhu, X., & Shi, Y. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.892125 · Cited by 124
Mehr, H. D., & Polat, H. (2021) · Health and Technology · doi:10.1007/s12553-021-00613-y · Cited by 117
“Hence, early prognosis of PCOS which mostly relies on both physical symptoms (e.g., abnormal hair growing under females ’ chin) and biochemical and clinical examinations is an essential issue and it can be beneficial in the treatment process [3, 4].”
BackgroundAggarwal, S., & Pandey, K. (2023) · Expert Systems with Applications · doi:10.1016/j.eswa.2023.119532 · Cited by 91
Long‐term health outcomes in young women with polycystic ovary syndrome: A narrative review
Allen, L. A., Shrikrishnapalasuriyar, N., & Rees, D. A. (2022) · Clinical Endocrinology · doi:10.1111/cen.14609 · Cited by 62
Mendelian randomization analyses for PCOS: evidence, opportunities, and challenges
Wang, C., Wu, W., Yang, H., Ye, Z., Zhao, Y., Liu, J., & Mu, L. (2022) · Trends in Genetics · doi:10.1016/j.tig.2022.01.005 · Cited by 81
Polycystic Ovary Syndrome (PCOS): Symptoms, Causes, and Treatment
Bai, H., Ding, H., & Wang, M. (2024) · Clinical and Experimental Obstetrics & Gynecology · doi:10.31083/j.ceog5105126 · Cited by 89
Metformin for diabetes prevention: update of the evidence base
Gottwald‐Hostalek, U., & Campbell, I. W. (2021) · Current Medical Research and Opinion · doi:10.1080/03007995.2021.1955667 · Cited by 80
Spremović-Radjenović, S., Pupovac, M., Andjić, M., Bila, J. S., Sreckovic, S. D., Gudović, A., Dragaš, B., & Radunović, N. V. (2022) · Biomedicines · doi:10.3390/biomedicines10010131 · Cited by 78
Optimized Machine Learning for the Early Detection of Polycystic Ovary Syndrome in Women
Panjwani, B., Yadav, J., Mohan, V., Agarwal, N., & Agarwal, S. (2025) · Sensors · doi:10.3390/s25041166 · Cited by 77
“…one of the key elements causing increased androgen levels and reduced oocyte quality; evidence from large cohorts suggests that IR and β cell dysfunction promote the progression to impaired glucose homeostasis, resulting in a high probability of dysglycemic conditions in patients with PCOS [11,12].”
Profile of Bile Acid Metabolomics in the Follicular Fluid of PCOS Patients
Yang, X., Wu, R., Qi, D., Fu, L., Song, T., Wang, Y., Bian, Y., & Shi, Y. (2021) · Metabolites · doi:10.3390/metabo11120845 · Cited by 67
Hibiscus sabdariffa in Diabetes Prevention and Treatment—Does It Work? An Evidence-Based Review
Jamrozik, D., Borymska, W., & Kaczmarczyk-Żebrowska, I. (2022) · Foods · doi:10.3390/foods11142134 · Cited by 73
Liu, Q., Tang, B., Zhu, Z., Kraft, P. L., Deng, Q., Stener‐Victorin, E., & Jiang, X. (2022) · Diabetologia · doi:10.1007/s00125-022-05746-x · Cited by 63
Advancements in lead therapeutic phytochemicals polycystic ovary syndrome: A review
Luo, E., Jiang, H., Chen, W., Wang, Y., Tang, M., Guo, W., Diao, H., Cai, N.-Y., Yang, X., Bian, Y., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1065243 · Cited by 61
Yang, Z., Fu, H., Su, H., Cai, X., Wang, Y., Hong, Y., Hu, J., Xie, Z., & Wang, X. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1017147 · Cited by 53
Sun, W., Kou, X., Wu, C., Fan, G., Li, T., Cheng, X., Xu, K., Suo, A., & Tao, Z. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.124301 · Cited by 48
Quality of Life of Women with Polycystic Ovary Syndrome
Ligocka, N., Chmaj-Wierzchowska, K., Wszołek, K., Wilczak, M., & Tomczyk, K. (2024) · Medicina · doi:10.3390/medicina60020294 · Cited by 58
Yuan, S., Merino, J., & Larsson, S. C. (2023) · Diabetologia · doi:10.1007/s00125-023-05879-7 · Cited by 47
Poojary, P. S., Nayak, G., Panchanan, G., Rao, A. C., Kundapur, S. D., Kalthur, S. G., Mutalik, S., Adiga, S. K., Zhao, Y., Bakkum-Gamez, J. N., et al. (2022) · Endocrinology · doi:10.1210/endocr/bqac097 · Cited by 41
Yin, G., Chen, F., Chen, G., Yang, X., Huang, Q., Chen, L., Chen, M., Zhang, W., Ou, M., Cao, M., et al. (2022) · Journal of Ovarian Research · doi:10.1186/s13048-022-01051-8 · Cited by 38
Polycystic ovary syndrome and adipose tissue
Lemaître, M., Christin‐Maître, S., & Kerlan, V. (2023) · Annales d Endocrinologie · doi:10.1016/j.ando.2022.11.004 · Cited by 40
Li, X., Liu, X., Zuo, Y., Gao, J., Liu, Y., & Zheng, W. (2021) · Medicine · doi:10.1097/md.0000000000026521 · Cited by 39
“Studies([5,6]) have shown that the incidence of diabetes in PCOS women between 20 and 40years old is as high as 20% to 40%.”
BackgroundGonadal dysfunction in women with diabetes mellitus
Zaimi, M., Michalopoulou, O., Stefanaki, K., Kazakou, P., Vasileiou, V., Ψαλτοπούλου, Θ., Karagiannakis, D. S., & Paschou, S. Α. (2024) · Endocrine · doi:10.1007/s12020-024-03729-z · Cited by 35
“Interestingly, while indicating a positive association between higher BMI, higher testosterone levels, and lower SHBG and the development of T2DM, a two-sample Mendelian randomization study did not fi nd an association between the genetic risk of PCOS and that of T2DM [51].”
BackgroundInfluentialCao, Z., Zhou, Q., An, J., Guo, X., Jia, X., & Qiu, Y. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s525651 · Cited by 34
“23,25,27,28,30 Epigenetic studies have revealed alterations in DNA methylation and gene expression in ovarian granulosa cells, adipose tissue, and skeletal muscle of PCOS patients.”
Broadening horizons: the role of ferroptosis in polycystic ovary syndrome
Wang, M., Zhang, B.-Q., Ma, S., Xu, Y. J., Zhao, D.-H., Zhang, J., Li, C.-J., Zhou, X., & Zheng, L. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1390013 · Cited by 37
“PCOS has transcended the fi eld of obstetrics and gynecology and affects various signi fi cant systems throughout the body, seriously threatening women ’ s physical and mental health, affecting their quality of life, and causing lifelong endocrine and metabolic diseases (130, 131) (Figure 3).”
BackgroundType 2 Diabetes Mellitus in Patients With Polycystic Ovary Syndrome
Agrawal, A., Dave, A., & Jaiswal, A. (2023) · Cureus · doi:10.7759/cureus.46859 · Cited by 40
Dwivedi, A. K., Vishwakarma, D., Dubey, P., & Reddy, S. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad067 · Cited by 29
Osibogun, O. I., Ogunmoroti, O., Kolade, O. B., Hays, A. G., Okunrintemi, V., Minhas, A., Gulati, M., & Michos, E. D. (2022) · Journal of Women s Health · doi:10.1089/jwh.2021.0608 · Cited by 28
“19 To reduce the burden of CVD among women with PCOS, early detection of clinical CVD can be facilitated by the measurement of surrogate markers of subclinical atherosclerosis such as coronary artery calcification (CAC).”
Zhang, W., Peng, C., Xu, L., Zhao, Y., Huang, C., & Lu, L. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1494852 · Cited by 30
Endocrine and metabolic effects of GLP-1 receptor agonists on women with PCOS, a narrative review
Monney, M., Mavromati, M., Leboulleux, S., & Gariani, K. (2025) · Endocrine Connections · doi:10.1530/ec-24-0529 · Cited by 30
Jiang, H., Si, M., Tian, T., Shi, H., Huang, N., Chi, H., Yang, R. J., Long, X., & Qiao, J. (2023) · European journal of medical research · doi:10.1186/s40001-023-01174-8 · Cited by 28
“PCOS has diverse lifelong clinical manifestations of reproductive, metabolic, and psychological disorders, such as anovulatory infertility, dyslipidemia, obesity, impaired glucose tolerance (IGT), Type 2 diabetes mellitus (T2DM), insulin resistance (IR), cardiovascular disease, low self-esteem, psychosexual dysfunctio…”
BackgroundWang, J., Wang, B., Li, C., Meng, T., Liu, C., Chen, J., & Guo, Y. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1569694 · Cited by 24
Wahid, S., Ramli, M. D. C., Fazleen, N. E., Naim, R. M., & Mokhtar, M. H. (2024) · Life · doi:10.3390/life14010150 · Cited by 26
“In addition, it is associated with multiple symptoms, such as ovarian enlargement [3], abdominal obesity [4], impaired metabolism disorder [5], insulin resistance [5], type 2 diabetes [6], and dyslipidemia [7].”
BackgroundGuo, F., Huang, Y., Fernando, T., & Shi, Y. (2022) · Reproductive Sciences · doi:10.1007/s43032-022-00845-x · Cited by 25
Assessment of Type 2 Diabetes Risk in Young Women with Polycystic Ovary Syndrome
Livadas, S., Paparodis, R. D., Anagnostis, P. G., Gambineri, A., Bjekić-Macut, J., Petrović, T., Yıldız, B. O., Micić, D., Mastorakos, G. P., & Μacut, D. (2023) · Diagnostics · doi:10.3390/diagnostics13122067 · Cited by 24
“Accordingly, normal-weight PCOS women should be counseled to avoid weight gain which could confer this risk [18].”
BackgroundInfluentialDema, H., Paska, A. V., Kouter, K., Katrašnik, M., Jensterle, M., Janež, A., Oblak, A., Škodlar, B., & Bon, J. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45040178 · Cited by 24
“In the presence of metabolic syndrome, patients are also at risk of developing cardiovascular disease, non-alcoholic fatty liver disease, endometrial hyperplasia and cancer, as well as some other cancers [7,8].”
BackgroundHe, Y., Deng, S., Wang, Y., Wang, X., Huang, Q., Cheng, J., Wang, D., & Lyu, G. (2025) · Scientific Reports · doi:10.1038/s41598-024-84338-8 · Cited by 26
Cussen, L., McDonnell, T., Miller, C., McIlroy, M., & O’Reilly, M. (2025) · Reproduction · doi:10.1530/rep-25-0102 · Cited by 22
Geraci, G., Riccio, C., Oliva, F. G., Gabrielli, D., Colivicchi, F., Grimaldi, M., Facchinetti, F., & Unfer, V. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1520490 · Cited by 24
The Current and Emerging Role of Statins in the Treatment of PCOS: The Evidence to Date
Kolnikaj, T. S., Herman, R., Janež, A., & Jensterle, M. (2024) · Medicina · doi:10.3390/medicina60020244 · Cited by 23
“These abnormalities can act as vital risk factors, increasing the chances of developing type 2 diabetes, coronary heart disease, and stroke [68].”
BackgroundMazloomi, S., Sheikh, N., Farimani, M. S., & Pilehvari, S. (2021) · International Journal of Endocrinology · doi:10.1155/2021/9949753 · Cited by 20
Pourahmad, B., Majidnia, M., Saniee, N., Riyahifar, S., & Moradi, Y. (2025) · BMC Women s Health · doi:10.1186/s12905-025-03927-5 · Cited by 18
“However, a study by Tiantian Zhu et al. found no significant association between genetic predisposition to PCOS and the risk of stroke [40].”
InfluentialPCOS health-related quality-of-life and depressive symptoms across the lifespan: Comparative study
Wright, P. J., Tavakoli, A. S., & Corbett, C. F. (2023) · Journal of Women & Aging · doi:10.1080/08952841.2023.2230112 · Cited by 21
Arora, S., Vedpal, & Chauhan, N. (2024) · Multimedia Tools and Applications · doi:10.1007/s11042-024-19707-6 · Cited by 20
A Narrative Review of Quercetin’s Role as a Bioactive Compound in Female Reproductive Disorders
Khamineh, Y., Ghiasvand, M., Panahi-Alanagh, S., Rastegarmand, P., Zolghadri, S., & Stanek, A. (2025) · Nutrients · doi:10.3390/nu17071118 · Cited by 18
“It is a leading cause of anovulatory infertility, accounting for approximately 80% of cases [41] and is frequently associated with metabolic conditions such as insulin resistance (IR), obesity, and an increased risk of type 2 diabetes and cardiovascular disease [42–44].”
Kang, D., Wang, X., Liu, W. Y., Chen, Y., Xue, F.-R., Song, C.-R., Dong, Y., Zhai, J., Liang, C., & Li, J. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04610-0 · Cited by 16
“Polycystic ovary syndrome (PCOS) poses a significant clinical challenge due to its heterogeneous manifestations and complex comorbidities, including insulin resistance (IR) [1], metabolic syndrome [2], and elevated risks of type 2 diabetes and cardiovascular diseases [3].”
Shamim, H., Jean, M., Umair, M., Muddaloor, P., Farinango, M., Ansary, A., Dakka, A., Nazir, Z., White, C. T., Habbal, A. B., et al. (2022) · Cureus · doi:10.7759/cureus.28462 · Cited by 20
Jin, L., Yu, J., Chen, Y., Pang, H., Sheng, J., & Huang, H. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.689897 · Cited by 17
“MR has been already proven powerful for resolving controversies about PCOS: while epidemiologic studies suggested that women with PCOS were more likely to experience type 2 diabetes mellitus, coronary heart disease, or stroke, MR detected no genetic causality between these diseases and PCOS (Zhu et al., 2020).”
BackgroundMethodCircadian rhythm disruption and polycystic ovary syndrome: a systematic review and meta-analysis
Heydari, T., & Ramdass, P. V. A. K. (2025) · AJOG Global Reports · doi:10.1016/j.xagr.2025.100479 · Cited by 19
Simons, P. I. H. G., Cornelissen, M. E. B., Valkenburg, O., Onland‐Moret, N. C., van der Schouw, Y. T., Stehouwer, C. D. A., Burgess, S., & Brouwers, M. C. G. J. (2021) · Clinical Endocrinology · doi:10.1111/cen.14593 · Cited by 16
Li, X., Xiao, H., Ma, Y., Zhou, Z., & Chen, D. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.905716 · Cited by 15
“Using cross-trait LDSC, PCOS shows a moderate positive genetic correlation with T2D, in agreement with previous studies (Zhu et al., 2021).”
Resultde Medeiros, S. F., de Medeiros, A. K. L. W. Y., de Medeiros, M. A. S., Carvalho, A. B. D. S., Yamamoto, M. M., Soares, J. M., & Baracat, E. C. (2023) · Hormone and Metabolic Research · doi:10.1055/a-2207-0739 · Cited by 15
Bays, H. E., Khera, A., Blaha, M. J., Budoff, M. J., & Toth, P. P. (2021) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2021.100176 · Cited by 13
Psychological Experiences in Women with Polycystic Ovary Syndrome: A Qualitative Study
Farajzadegan, Z., Kazemi, A., Salehi, M., & ZareMobini, F. (2023) · Iranian Journal of Nursing and Midwifery Research · doi:10.4103/ijnmr.ijnmr_139_22 · Cited by 12
Effect of High-intensity Interval Training on Endothelial Function in Type 2 Diabetic Females
Abdi, S., Tadıbı, V., & Sheikholeslami‐Vatani, D. (2021) · Asian Journal of Sports Medicine · doi:10.5812/asjsm.113566 · Cited by 12
Alarcón-Granados, M. C., Moreno-Ortíz, H., Esteban-Pérez, C. I., Ferrebuz, A., Villalba, G. E. C., & Forero‐Castro, M. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e09673 · Cited by 12
Lai, S., Jin, Q., Wang, D., Li, T., & Wang, X. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1302312 · Cited by 15
“Nevertheless, previous mendelian randomization studies did not found association of genetically predicted polycystic ovary syndrome with risk of coronary heart disease (47, 48), indicating that our results are not affected by confounding role of polycystic ovary syndrome.”
Olaniyi, K. S., & Areloegbe, S. E. J. (2022) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2022.106179 · Cited by 11
Patil, P. B., Rashmi, M., Natesha, B. V., & Shetty, R. D. (2025) · International Journal of Information Technology · doi:10.1007/s41870-025-03044-4 · Cited by 14
Polyendocrine metabolic ovarian syndrome in pregnancy: pathophysiology and outcomes
Teede, H. J., Vanky, E., Piltonen, T., Stener‐Victorin, E., Moran, L., & Khomami, M. B. (2026) · Nature Reviews Endocrinology · doi:10.1038/s41574-026-01261-w · Cited by 13
Yifu, P. (2023) · BMC Medical Genomics · doi:10.1186/s12920-023-01581-0 · Cited by 13
Association of lipid profile and obesity in patients with polycystic ovary syndrome
Parveen, S., Khan, S., Khan, M. M., Gupta, B., Ahmad, A., & Alam, R. (2024) · Endocrine Regulations · doi:10.2478/enr-2024-0009 · Cited by 13
Jabczyk, M., Nowak, J., Jagielski, P., Hudzik, B., Borszcz, J., & Zubelewicz‐Szkodzińska, B. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1398017 · Cited by 11
Lahoda, D. O., Artyomenko, V., Velychko, V. I., & Danylchuk, H. O. (2023) · Journal of Medicine and Life · doi:10.25122/jml-2023-0057 · Cited by 14
miR-34a-5p modulation of polycystic ovary syndrome via targeting the NOTCH signaling pathway
Zhang, K., Wang, X., Liu, F., Lin, H., Wang, Y., Zhao, M., Wang, X., Chu, Y., & Xu, L. (2025) · Journal of Ovarian Research · doi:10.1186/s13048-025-01623-4 · Cited by 10
Guan, G., Yifu, P., Xiaofeng, T., Sun, Q., Yuan, G., Yang, W. S., Conghui, H., & Zhu, Z. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1337562 · Cited by 11
“Fourteen independent SNPs of PCOS were used according to a previous article (36).”
MethodChao Nang Qing prescription promotes granulosa cell apoptosis and autophagy by targeting GATA3
Luo, L., Shen, Y., Ning, D., Tang, M., Xie, L., Zheng, Q., & Ouyang, Z. (2023) · Gynecological Endocrinology · doi:10.1080/09513590.2023.2223724 · Cited by 9
“Moreover, the multiple pathogenic features of PCOS may increase the risks of cardiovascular disease, diabetes mellitus, nonalcoholic fatty liver disease, and other illnesses [3–6].”
BackgroundPCOS Diagnosis With Commonly Known Diseases Using Hybrid Machine Learning Algorithms
Aggarwal, S., & Pandey, K. (2023) · International Conference on Contemporary Computing and Informatics (IC3I) · doi:10.1109/ic3i59117.2023.10397717 · Cited by 11
“Zhu et al.[11] uses the sample Mendelian Randomization (MR) for gaining knowledge about the relationship between PCOS and type 2 diabetes, stroke and coronary heart diseases.”
BackgroundWright, P. J., Burts, C., Harmon, C., & Corbett, C. F. (2025) · JMIR Infodemiology · doi:10.2196/68469 · Cited by 8
“Obesity, insulin resistance, and dyslipidemia are common clinical features in women with PCOS and increase the risk for cardiometabolic diseases and reproductive cancers by ≥50% [3] while negatively impacting women’s health-related quality-of-life and psychological morbidity [4].”
Classification and identification of risk factors for type 2 diabetes
Tang, S., Zhao, X., An, X., Sun, W., Kang, X., Sun, Y., Jiang, L., Gao, Q., Li, Z., Ji, H., et al. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v16.i2.100371 · Cited by 10
Palomba, S., Costanzi, F., Cannarella, R., Votino, R., Calogero, A. E., Signore, F., & Caserta, D. (2025) · Fertility and Sterility · doi:10.1016/j.fertnstert.2025.04.026 · Cited by 9
Exploring the Experiential Journey of Women with PCOS Across the Lifespan: A Qualitative Inquiry
Wright, P. J., Dawson, R. M., & Corbett, C. F. (2024) · International Journal of Women s Health · doi:10.2147/ijwh.s467737 · Cited by 8
Zhang, X., Huangfu, Z., & Wang, S. (2023) · Endocrine · doi:10.1007/s12020-023-03467-8 · Cited by 8
“Although a two-sample MR analysis previously suggested no correlation between genetically-predicted PCOS and the risk of CAD [24] or stoke [25], the association between PCOS and other common CVDs, including AF, arrhythmia, HF, hypertension (HT), MI, peripheral artery disease (PAD), PVD and VTE, has…”
BackgroundResultAtkins, P., TOMLINSON, G. A., Feig, D. S., & MiTy Collaborative Group (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3713 · Cited by 7
He, Y., Wang, Y., Wang, X., Deng, S., Wang, D., Huang, Q., & Lyu, G. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1431200 · Cited by 7
Metabolomic Profiling Reveals Biomarkers in Coronary Heart Disease Comorbidity
Geng, C., Liang, B., Kong, Z., Feng, L., Wang, J., Si, Q., & Jiang, P. (2024) · Journal of Diabetes Research · doi:10.1155/jdr/8559677 · Cited by 8
Can dysglycemia in OGTT be predicted by baseline parameters in patients with PCOS?
Livadas, S., Bothou, C., Kuliczkowska-Płaksej, J., Robeva, R., Vryonidou, A., Macut, J. B., Androulakis, I., Opalic, M., Mouslech, Z., Milewicz, A., et al. (2022) · Endocrine Connections · doi:10.1530/ec-21-0358 · Cited by 13
Liu, L., Gao, Q., Huang, J., Yu, Q., Liu, K., Tong, Y., Zeng, Y., Li, Y., Liang, Y., Hong, Y., et al. (2026) · Clinical Proteomics · doi:10.1186/s12014-025-09575-z · Cited by 6
“Beyond reproductive challenges, women with PCOS face an increased risk of pregnancy-related complications and comorbidities, including type 2 diabetes mellitus, hypertension-related disorders, cardiovascular diseases, mental health conditions (depression and anxiety), and certain malignancies [4–6].”
Su, N., Li, J., Xia, Y., Huang, C., & Chen, L. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1393847 · Cited by 6
Zadhoush, R., Naeini, A. A., Feizi, A., Naghshineh, E., & Ghazvini, M. A. (2023) · International Journal of Preventive Medicine · doi:10.4103/ijpvm.ijpvm_229_21 · Cited by 7
“Women with PCOS are more prone to be at risk for several complications, namely insulin resistance, diabetes, and cardiovascular diseases, which make it a critical problem for patients and the healthcare system as well.[26,27] We found that garlic supplementation can decrease weight, BMI, and WC.”
BackgroundHan, X., Zhang, M., Jiang, S., & Chun-ni, H. (2022) · Computational and Mathematical Methods in Medicine · doi:10.1155/2022/4820835 · Cited by 6
RetractedMárquez‐Arrico, C. F., Pelechá-Salvador, M., Fernández-Reyes, M., Donat, F. J. S., Perea‐Galera, L., Hermenejildo, J., Abad‐Jiménez, Z., Silvestre‐Rangil, J., Morillas, C., Víctor, V. M., et al. (2025) · Antioxidants · doi:10.3390/antiox14050507 · Cited by 5
“As a whole, women with PCOS are at an increased risk of cardiometabolic outcomes, such as type 2 diabetes or cardiovascular disease [7].”
Jackuliak, P., Jankovský, M., Kovářová, M., Voller, J., Feitscherova, C., & Varga, I. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1582039 · Cited by 6
Nie, G., Liu, M., Yang, L., Li, C., Qu, C., Wang, J., Mei, J., Wang, Y., Han, L., Zhang, X., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1733950 · Cited by 6
“This exacerbates insulin resistance and in fl ammation, leading to complications such as metabolic syndrome, thereby perpetuating the pathological cycle of PCOS (91 – 93).”
Zhao, X., Wang, J., Sun, D., Xu, D., & Lu, Y. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae375 · Cited by 16
Pharmacological Management of Obesity in Patients with Polycystic Ovary Syndrome
Kourtidou, C., & Τζιόμαλος, Κ. (2023) · Biomedicines · doi:10.3390/biomedicines11020496 · Cited by 7
Yang, Z. F., Liu, F.-T., Bai, J., Ye, Z., Yin, J., Peng, T., Shan, H., Yu, Y., Zhou, P., & Li, R. (2023) · Biology of Reproduction · doi:10.1093/biolre/ioad017 · Cited by 6
Status Gizi dan Gaya Hidup Wanita dengan Sindrom Ovarium Polikistik (PCOS) di Yogyakarta
Kurniawati, E. Y., Hutabarat, N. C., & Noviasari, E. (2023) · JURNAL KESEHATAN PERINTIS (Perintis s Health Journal) · doi:10.33653/jkp.v10i1.971 · Cited by 8
Chen, S., Guo, Z., & Yu, Q. (2023) · Human Genomics · doi:10.1186/s40246-023-00550-z · Cited by 6
“Future testing of large samples of GWAS for different PCOS subtypes may contribute to better MR work on PCOS and other diseases and clearer causality [38].”
BackgroundCirculating microparticles as indicators of cardiometabolic risk in PCOS
Yalameha, B., Nejabati, H. R., & Nouri, M. (2022) · Clinica Chimica Acta · doi:10.1016/j.cca.2022.06.019 · Cited by 5
Jiang, H., Chen, L., Huang, N., Shi, H., Chi, H., Yang, R. J., Long, X., & Qiao, J. (2023) · Journal of Ovarian Research · doi:10.1186/s13048-023-01208-z · Cited by 4
Jia, M.-J., Zhou, L., Liu, X.-N., & Li, H.-L. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1433612 · Cited by 5
“With the increasing recognition of lifestyle factors such as sedentary behaviors and environmental influences, PCOS is not only a reproductive health concern but also significantly increases the risk of developing chronic conditions such as type 2 diabetes, cardiovascular diseases, and stroke (3).”
Shao, S., Xu, Q., Zi, Y., Zheng, X., Chen, S., Qin, C., Zhao, H., & Li, X. (2024) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2024.12.043 · Cited by 6
Metadata
- Authors
- Zhu, T., Cui, J., & Goodarzi, M. O.
- Affiliations
- Cedars-Sinai Medical Center (US)
- Corresponding author
- Goodarzi, Mark O.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2020-11-06
- Volume
- 70
- Issue
- 2
- Pages
- 627-637
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W3095084496
- Cited by
- 226
- References
- 53
- Citations by year
- 2026: 24 · 2025: 41 · 2024: 36 · 2023: 83 · 2022: 29 · 2021: 13
- FWCI
- 27.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- polycystic ovary syndrome, type 2 diabetes, coronary artery disease, stroke, cardiometabolic disease, causal inference, genetic risk prediction, sex differences, stroke subtypes, obesity, testosterone, sex hormone-binding globulin
- MeSH terms
- Adult, Coronary Disease, Diabetes Mellitus, Type 2, Female, Humans, Polycystic Ovary Syndrome, Risk, Comorbidity, Case-Control Studies, Stroke, Mendelian Randomization Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.